There are no studies documenting the percentage of doctors taking the drugs. But physicians “are a good litmus test for drugs ...

It turns out that the anti-obesity space isn't growing as fast as Eli Lilly or analysts anticipated, resulting in ...

Not all growth stocks worth buying these days focus on the artificial intelligence field. There are many exciting ones in ...

In a recent press release, Eli Lilly's management said that the U.S. incretin market, which includes drugs like Zepbound and Mounjaro ... we should look at the rest of Eli Lilly's portfolio.

Eli Lilly's strong momentum in blockbuster therapies and promising pipeline signals future growth, but competition and ...

Higher volumes of drugs like Mounjaro, Zepbound, Verzenio ... Lilly’s 2025 outlook looks decent. Shares were down around 1% in pre-market trading. Lilly’s stock has risen 19.4% in the past ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

When Jeanne began to seriously consider taking Zepbound, one of the new-generation weight-loss drugs, she had the briefest of ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...